Clinical Trials Logo

Hyperphosphatemia clinical trials

View clinical trials related to Hyperphosphatemia.

Filter by:

NCT ID: NCT01854437 Completed - Hyperphosphatemia Clinical Trials

The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

Start date: June 2012
Phase: Phase 1
Study type: Observational [Patient Registry]

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

NCT ID: NCT01852682 Completed - Hyperphosphatemia Clinical Trials

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

NCT ID: NCT01850641 Completed - Hemodialysis Clinical Trials

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Start date: April 29, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.

NCT ID: NCT01850602 Completed - Hemodialysis Clinical Trials

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Start date: April 23, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia

NCT ID: NCT01833494 Completed - Clinical trials for Hemodialysis Patients With Hyperphosphatemia

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Start date: March 18, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

NCT ID: NCT01818687 Terminated - Clinical trials for Chronic Kidney Disease

Safety and Tolerability Study of MCI-196

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the safety and tolerability of colestilan (MCI-196) in paediatric subjects (aged 2 years to <18 years) with CKD stages 3b to 5, diagnosed with hyperphosphataemia, who are not on dialysis.

NCT ID: NCT01814917 Terminated - Clinical trials for Chronic Kidney Disease

Long-term Extension Study of MCI-196

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The Primary Objectives of this study are to assess the long-term efficacy of treatment with colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of treatment with colestilan (MCI-196) (including combination therapy).

NCT ID: NCT01814904 Terminated - Clinical trials for Chronic Kidney Disease

Dose-finding Study of MCI-196

Start date: April 2014
Phase: Phase 3
Study type: Interventional

The Primary Objective of this study is to determine the initial starting doses of colestilan (MCI-196) in paediatric subjects with Chronic Kidney Disease Stage 5 on Dialysis and with Hyperphosphataemia.

NCT ID: NCT01755078 Completed - Hemodialysis Clinical Trials

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.

NCT ID: NCT01742611 Completed - Clinical trials for Chronic Kidney Disease

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start date: March 2013
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.